Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7473.084 | 1.4170 | 1.3739 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7473.084 | 1.7318 | 1.6200 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7473.084 | 1.1522 | 1.1443 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7473.084 | 1.6031 | 1.5224 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7473.084 | 0.6769 | 0.6509 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7474.084 | 0.8802 | 0.9065 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7474.084 | 1.2635 | 1.1836 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7474.084 | 0.8579 | 0.8882 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7474.084 | 0.8540 | 0.8849 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7474.084 | 1.4823 | 1.3185 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7474.084 | 1.3374 | 1.2307 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7474.084 | 1.3991 | 1.2688 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7474.084 | 1.3231 | 1.2217 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7474.084 | 0.0007 | -0.8699 | 2.6631 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7475.084 | 1.0246 | 1.0176 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7475.084 | 1.0941 | 1.0658 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7475.084 | 1.0385 | 1.0274 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7475.084 | 1.0794 | 1.0557 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7475.084 | 1.4014 | 1.2581 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7475.084 | 1.3033 | 1.1999 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7475.084 | 1.4041 | 1.2596 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7475.084 | 0.8836 | 0.9129 | 2.7804 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7475.084 | 0.6811 | 0.7420 | 2.7804 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7477.084 | 0.9097 | 0.8099 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7477.084 | 1.0176 | 1.0372 | 0.9476 |